Azelastine Nasal Spray in Non-Hospitalized Subjects with Mild COVID-19 Infection: A Randomized Placebo-Controlled, Parallel-Group, Multicentric, Phase II Clinical Trial

Azelastine Nasal Spray in Non-Hospitalized Subjects with Mild COVID-19 Infection: A Randomized Placebo-Controlled, Parallel-Group, Multicentric, Phase II Clinical Trial

Nasal spray treatments that inhibit the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) entry into nose and nasopharynx at early stages can be an appropriate approach to stop or delay the progression of the disease. We performed a prospective, randomized, double-blind, placebo-controlle...

Full description

Saved in:
Bibliographic Details
Main Authors: Peter Meiser, Michael Flegel, Frank Holzer, Dorothea Groß, Charlotte Steinmetz, Barbara Scherer, Rajesh Jain, CARVIN-II Study Group
Format: Article
Language:English
Published: MDPI AG 2024-12-01
Series:Viruses
Subjects:
COVID-19
azelastine
nasal spray
SARS-CoV-2
viral load
COVID-19 related hospitalization
Online Access:https://www.mdpi.com/1999-4915/16/12/1914
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1999-4915/16/12/1914

Similar Items